Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from bioAffinity Technologies, Inc. ( (BIAF) ) is now available.
On July 25, 2025, bioAffinity Technologies, Inc. held its annual meeting where stockholders approved a reverse stock split of the company’s common stock. The board decided on a 1-for-30 reverse split, which became effective on September 18, 2025, and aimed to comply with Nasdaq’s minimum bid price requirement. This adjustment will not affect stockholders’ percentage ownership, except for those receiving cash instead of fractional shares.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.
The overall stock score is primarily driven by significant financial challenges, including negative profitability and increasing leverage. Technical analysis provides mixed signals, with the stock trading below key moving averages. Valuation concerns are underscored by a negative P/E ratio and lack of dividend yield, indicating ongoing financial instability.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive tests for detecting early-stage cancer and other lung diseases. Their primary product, CyPath® Lung, is marketed as a Laboratory Developed Test by their subsidiary, Precision Pathology Laboratory Services.
Average Trading Volume: 7,709,811
Technical Sentiment Signal: Sell
Current Market Cap: $10.36M
For a thorough assessment of BIAF stock, go to TipRanks’ Stock Analysis page.